B
Bull
Bull · 25%MRSN
$0.50
シナリオ価格
$29.080
+0.041 (+0.14%)終値時点
Loading chart…
- High
- 30.390
- Open
- 28.900
- VWAP
- 29.42
- Vol
- 712.46K
- Mkt Cap
- 244.11M
- Low
- 28.780
- Amount
- 20.96M
- EV/EBITDA, TTM
- 0.00
Mersana Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) and is engaged in developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company also focuses on adult oncology. Its pipeline includes tovorafenib (OJEMDA), DAY301, emiltatug ledadotin (Emi-Le), a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC). It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells.
Analyst Ratings (4)
+5.74% upside
Buy
4 Buy
0 Hold
0 Sell
Current: 29.08
安値
30.75
平均
30.75
高値
30.75
Wedbush
Neutral
$55.25
2025-11-13
Wedbush
2025-11-13
目標株価
$55.25
Neutral
BTIG
Neutral
$25
2025-11-13
BTIG
2025-11-13
目標株価
$25
Neutral
Truist
Hold
$36
2025-11-13
Truist
2025-11-13
目標株価
$36
Hold
Leerink
Market Perform
$29
2025-11-13
Leerink
2025-11-13
目標株価
$29
Market Perform
LifeSci Capital
Market Perform
$25
2025-11-13
LifeSci Capital
2025-11-13
目標株価
$25
Market Perform
バリュエーション指標
The current forward P/E ratio for Mersana Therapeutics Inc (MRSN) is -2.13, compared to its 5-year average forward P/E of -2.61.
Alphio AI Price Scenarios for MRSN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding MRSN
イベントタイムライン
ニュース
9.502-24Yahoo FinanceDay One Biopharmaceuticals Reports Strong 2025 Financial Results and Growth Outlook
8.501-06GlobenewswireDay One Acquires Mersana for $25 per Share, Expanding Oncology Pipeline
7.012-24PRnewswireHalper Sadeh Investigates Udemy and Others for Potential Violations
8.512-23GlobenewswireAlexander & Baldwin Acquired for $21.20 per Share, Valuing Deal at $2.3 Billion
7.012-17PRnewswireHalper Sadeh Investigates Mersana's Sale to Day One for Shareholder Rights Violations
MRSN FAQ — answered by Alphio AI
Mersana Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) and is engaged in developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company also focuses on adult oncology. Its pipeline includes tovorafenib (OJEMDA), DAY301, emiltatug ledadotin (Emi-Le), a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC). It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
4 analysts cover MRSN: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 30.75.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。